These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
418 related articles for article (PubMed ID: 35236415)
1. Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia. Yang X; Ma L; Zhang X; Huang L; Wei J Exp Hematol Oncol; 2022 Mar; 11(1):11. PubMed ID: 35236415 [TBL] [Abstract][Full Text] [Related]
2. High PD-L1 expression is associated with unfavorable clinical features in myelodysplastic neoplasms. Sampaio LR; Viana MA; de Oliveira VS; Ferreira BV; Melo MML; de Oliveira RTG; Borges DP; Magalhãesa SMM; Pinheiro RF Hematol Transfus Cell Ther; 2024; 46(2):146-152. PubMed ID: 37543491 [TBL] [Abstract][Full Text] [Related]
3. PD-1 signaling and inhibition in AML and MDS. Haroun F; Solola SA; Nassereddine S; Tabbara I Ann Hematol; 2017 Sep; 96(9):1441-1448. PubMed ID: 28643044 [TBL] [Abstract][Full Text] [Related]
4. The emerging role of immune checkpoint based approaches in AML and MDS. Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300 [TBL] [Abstract][Full Text] [Related]
5. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737 [TBL] [Abstract][Full Text] [Related]
6. Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment. Geng S; Xu R; Huang X; Li M; Deng C; Lai P; Wang Y; Wu P; Chen X; Weng J; Du X Front Immunol; 2022; 13():950134. PubMed ID: 36003379 [TBL] [Abstract][Full Text] [Related]
7. Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS. Yoyen-Ermis D; Tunali G; Tavukcuoglu E; Horzum U; Ozkazanc D; Sutlu T; Buyukasik Y; Esendagli G Sci Rep; 2019 Aug; 9(1):11697. PubMed ID: 31406210 [TBL] [Abstract][Full Text] [Related]
8. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice. Masarova L; Kantarjian H; Ravandi F; Sharma P; Garcia-Manero G; Daver N Adv Exp Med Biol; 2018; 995():97-116. PubMed ID: 30539507 [TBL] [Abstract][Full Text] [Related]
9. S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes. Cheng P; Eksioglu EA; Chen X; Kandell W; Le Trinh T; Cen L; Qi J; Sallman DA; Zhang Y; Tu N; Adams WA; Zhang C; Liu J; Cleveland JL; List AF; Wei S Leukemia; 2019 Aug; 33(8):2034-2046. PubMed ID: 30737486 [TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Abaza Y; Zeidan AM Cells; 2022 Jul; 11(14):. PubMed ID: 35883692 [TBL] [Abstract][Full Text] [Related]
14. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial. Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434 [TBL] [Abstract][Full Text] [Related]
15. BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Pericole FV; Lazarini M; de Paiva LB; Duarte ADSS; Vieira Ferro KP; Niemann FS; Roversi FM; Olalla Saad ST Front Oncol; 2019; 9():16. PubMed ID: 30761268 [TBL] [Abstract][Full Text] [Related]
17. Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints. Hidalgo-López JE; Kanagal-Shamanna R; Quesada AE; Thakral B; Hu Z; Mitsuhashi T; Yabe M; Garcia-Manero G; Bueso-Ramos CE Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S16-S25. PubMed ID: 28760297 [TBL] [Abstract][Full Text] [Related]
18. Transformation of myelodysplastic syndromes into acute myeloid leukemias. Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365 [TBL] [Abstract][Full Text] [Related]
19. The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype? Snow A; Zeidner JF Ther Adv Hematol; 2022; 13():20406207221112899. PubMed ID: 35898435 [TBL] [Abstract][Full Text] [Related]
20. STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia. Huang ZW; Zhang XN; Zhang L; Liu LL; Zhang JW; Sun YX; Xu JQ; Liu Q; Long ZJ Signal Transduct Target Ther; 2023 Sep; 8(1):391. PubMed ID: 37777506 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]